Edition:
United Kingdom

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

7.54USD
25 Apr 2018
Change (% chg)

$-0.17 (-2.20%)
Prev Close
$7.71
Open
$7.72
Day's High
$7.72
Day's Low
$7.51
Volume
1,768
Avg. Vol
6,084
52-wk High
$11.34
52-wk Low
$6.19

Chart for

About

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $147.73
Shares Outstanding(Mil.): 13.32
Dividend: --
Yield (%): --

Financials

  ORMP.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.95 -- --
ROI: -35.98 1.58 14.38
ROE: -49.39 2.41 16.07

BRIEF-Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study For Oral Insulin

* ORAMED INITIATES ITS 90-DAY PIVOTAL DOSE-RANGING CLINICAL STUDY FOR ORAL INSULIN Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

23 Apr 2018

BRIEF-Oramed Pharmaceuticals' Unit Enters Clinical Research Organization Services Agreement With Integrium

* SAYS ON FEB 14, A UNIT ENTERED CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT WITH INTEGRIUM EFFECTIVE AS OF NOV 1, 2017‍​

20 Feb 2018

BRIEF-Oramed receives approval for clinical study to treat NASH

* Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule

14 Nov 2017

Earnings vs. Estimates